CANCER 2020 10.1002/cncr.32809
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
Lee1, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

EUR J CANCER 2020 10.1016/j.ejca.2020.03.029
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

NAT COMMUN 2020 10.1038/s41467-020-16164-1
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests
Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

IN VIVO 2020 10.21873/invivo.11920
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2020 10.1016/j.jtho.2020.01.016
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Poirier1, JT; George, J; Owonikoko, TK; Berns, A; Brambilla, E; Byers, LA; Carbone, D; Chen, HJ; Christensen, CL; Dive, C; Farago, AF; Govindan, R; Hann, C; Hellmann, MD; Horn, L; Johnson, JE; Ju, YS; Kang, SM; Krasnow, M; Lee, J; Lee, SH; Lehman, J; Lok, B; Lovly, C; MacPherson, D; McFadden, D; Minna, J; Oser, M; Park, K; Park, KS; Pommier, Y; Quaranta, V; Ready, N; Sage, J; Scagliotti, G; Sos, ML; Sutherland, KD; Travis, WD; Vakoc, CR; Wait, SJ; Wistuba, I; Wong, KK; Zhang, H; Daigneault, J; Wiens, J; Rudin, CM; Oliver, TG

INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Ku1, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J MOL DIAGN 2020 10.1016/j.jmoldx.2019.10.015
Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology
Shin1, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY

Cancer Med 2020 10.1002/cam4.2868
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence
Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J CLIN ONCOL 2020 10.1200/JCO.19.00931
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Cho1, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2020 10.4143/crt.2019.186
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ

RESP MED 2020 10.1016/j.rmed.2019.105853
Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors
Im1, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH

BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

Oncoimmunology 2020 10.1080/2162402X.2020.1722023
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
Kim1, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

J THORAC ONCOL 2019 10.1016/j.jtho.2019.10.010
In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing
Park1, S; Lee, SH; Park, K

INT J CANCER 2019 10.1002/ijc.32235
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease
Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH

EUR J CANCER 2019 10.1016/j.ejca.2019.08.001
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

NAT COMMUN 2019 10.1038/s41467-019-12159-9
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

BMC CANCER 2019 10.1186/s12885-019-6044-z
NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors
Phi1, JH; Sun, CH; Lee, SH; Lee, S; Park, I; Choi, SA; Park, SH; Lee, JY; Wang, KC; Kim, SK; Yun, H; Park, CK

J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

ONCOLOGIST 2019 10.1634/theoncologist.2019-0070
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Keam1, B; Lee, KW; Lee, SH; Kim, JS; Kim, JH; Wu, HG; Eom, KY; Kim, S; Ahn, SH; Chung, EJ; Kwon, SK; Jeong, WJ; Jung, YH; Kim, JW; Heo, DS

J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Lancet Respir Med 2019 10.1016/S2213-2600(19)30053-0
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Zhou1, CC; Kim, SW; Reungwetwattana, T; Zhou, JY; Zhang, YP; He, JX; Yang, JJ; Cheng, Y; Lee, SH; Bu, LL; Xu, TT; Yang, L; Wang, C; Liu, T; Morcos, PN; Lu, Y; Zhang, L

CANCER RES TREAT 2019 10.4143/crt.2018.151
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

RADIOTHER ONCOL 2019 10.1016/j.radonc.2019.01.005
Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery
Cho1, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H

CANCER RES TREAT 2019 10.4143/crt.2018.117
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Kim1, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CANCER RES TREAT 2019 10.4143/crt.2018.125
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449
The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kim1, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC

CANCER RES TREAT 2019 10.4143/crt.2018.324
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Yoo1, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Kim1, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5
Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer
Moon1, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH

CANCER RES TREAT 2019 10.4143/crt.2018.132
Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
Lee1, SH; Lee, B; Shim, JH; Lee, KW; Md, JWY; Kim, SY; Kim, TY; Kim, YH; Ko, YH; Chung, HC; Yu, CS; Lee, J; Rha, SY; Kim, TW; Jung, KH; Im, SA; Moon, HG; Cho, S; Kang, JH; Kim, J; Kim, SK; Ryu, HS; Ha, SY; Il Kim, J; Chung, YJ; Kim, C; Kim, HL; Park, WY; Noh, DY; Park, K

CANCER RES TREAT 2019 10.4143/crt.2018.138
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Lee1, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ

RADIAT ONCOL 2018 10.1186/s13014-018-1196-6
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion
Kim1, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH

LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CLIN GENITOURIN CANC 2018 10.1016/j.clgc.2018.05.011
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Noneclear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
Park1, I; Lee, SH; Lee, JL

J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ

CLIN CANCER RES 2018 10.1158/1078-0432.CCR-17-3492
Integrin beta 3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Noh1, KW; Sohn, I; Song, JY; Shin, HT; Kim, YJ; Jung, K; Sung, M; Kim, M; An, S; Han, J; Lee, SH; Lee, MS; Choi, YL

J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038
Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication
Lee1, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ

LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009
Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma
Lee1, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM

Journal of thoracic disease 2018 10.21037/jtd.2018.04.127
The more and the heavier may not always be an answer
Pyo1, H; Lee, SH; Kim, J

PLoS One 2018 10.1371/journal.pone.0194730
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
Ku1, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

BRIT J CANCER 2018 10.1038/bjc.2017.465
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
Sun1, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer
Cho1, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
Cho1, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy
Park1, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011
Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Park1, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Oncoimmunology 2018 10.1080/2162402X.2017.1375642
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Kim1, HI; Kim, M; Lee, SH; Park, SY; Kim, YN; Kim, H; Jeon, MJ; Kim, TY; Kim, SW; Kim, WB; Kim, SW; Lee, DH; Park, K; Ahn, MJ; Chung, JH; Shong, YK; Kim, WG; Kim, TH

PLoS One 2018 10.1371/journal.pone.0189766
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
Park1, S; Ha, S; Lee, SH; Paeng, JC; Keam, B; Kim, TM; Kim, DW; Heo, DS

J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
Sun1, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K

J PATHOL 2017 10.1002/path.4950
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Noh1, KW; Lee, MS; Lee, SE; Song, JY; Shin, HT; Kim, YJ; Oh, DY; Jung, K; Sung, M; Kim, M; An, S; Han, J; Shim, YM; Zo, JI; Kim, J; Park, WY; Lee, SH; Choi, YL

NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer
Ku1, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2017 10.4143/crt.2016.424
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Lee1, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ

J CLIN ONCOL 2017 10.1200/JCO.2016.71.9096
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
Lee1, JK; Lee, J; Kim, S; Kim, S; Youk, J; Park, S; An, Y; Keam, B; Kim, DW; Heo, DS; Kim, YT; Kim, JS; Kim, SH; Lee, JS; Lee, SH; Park, K; Ku, JL; Jeon, YK; Chung, DH; Park, PJ; Kim, J; Kim, TM; Ju, YS

ONCOTARGET 2017
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
Ku1, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ

SCI REP-UK 2017 10.1038/s41598-017-12557-3
Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma
Kim1, S; Kim, JE; Kim, YH; Hwang, T; Kim, SK; Xu, WJ; Shin, JY; Kim, JI; Choi, H; Kim, HC; Cho, HR; Choi, A; Chowdhury, T; Seo, Y; Dho, YS; Kim, JW; Kim, DG; Park, SH; Kim, H; Choi, SH; Park, S; Lee, SH; Park, CK

CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors
Kim1, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J MED GENET 2017 10.1136/jmedgenet-2016-104390
Comprehensive somatic genome alterations of urachal carcinoma
Lee1, S; Lee, J; Sim, SH; Lee, Y; Moon, KC; Lee, C; Park, WY; Kim, NKD; Lee, SH; Lee, H

BMC Cancer. 2017 May 15;17(1):330. doi: 10.1186/s12885-017-3282-9.
Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma
Lee Y11, Park S2, Lee SH3,4, Lee H5.

Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

Lancet Respir Med. 2017 Feb;5(2):e10. doi: 10.1016/S2213-2600(17)30010-3.
Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC
Lee SH11, Lee JK2.

Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283.
Osimertinib for the treatment of non-small cell lung cancer
Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.

RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015
A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer
Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K

Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559.
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
Lee SH11, Lee JK2, Ahn MJ1, Kim DW2, Sun JM1, Keam B2, Kim TM2, Heo DS2, Ahn JS1, Choi YL3, Min HS4, Jeon YK4, Park K1.

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

Cancer Res Treat. 2017 Jan;49(1):193-203. doi: 10.4143/crt.2015.473. Epub 2016 Jun 27.
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
Kim BS11, Seol HJ2, Nam DH2, Park CK3, Kim IH4, Kim TM5, Kim JH6, Cho YH6, Yoon SM7, Chang JH8, Kang SG8, Kim EH8, Suh CO9, Jung TY10, Lee KH11, Kim CY12, Kim IA13, Hong CK14, Yoo H15, Kim JH16, Kang SH17, Kang MK18, Kim EY19, Kim SH20, Chung DS21, Hwang SC22, Song JH23, Cho SJ24, Lee SI25, Lee YS26, Ahn KJ27, Kim SH28, Lim DH29, Gwak HS30, Lee SH31, Hong YK32.

Cancer Res Treat. 2017 Jan;49(1):129-140. doi: 10.4143/crt.2015.466. Epub 2016 May 18.
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
Cha Y11, Kim YJ2, Lee SH1,3, Kim TM1, Choi SH4, Kim DW1, Park CK5, Kim IH6, Kim JH2, Kim E7, Choi B7, Kim CY8, Kim IA9, Heo DS1.

JOURNAL OF SURGICAL ONCOLOGY, DEC 1 2016, 114(7):888-894, DOI: 10.1002/jso.24412
Prognostic significance of clinical and F-18-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients
Cho JK1, Hyun SH, Choi JY, Choi N, Kim MJ, Lee SH, Baek KH, Jeong HS

J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130.
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision
Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.

Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17.
Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study
Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.

Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5.
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells
Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26.
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria
Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14.
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.

Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15.
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.

Oncotarget. 2016 Apr 26;7(17):23874-84. doi: 10.18632/oncotarget.8074.
Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
Lee B11,2, Lee T1, Lee SH3,2, Choi YL1,2, Han J1.

EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652
Pembrolizumab for the treatment of non-small cell lung cancer
Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

Thyroid. 2016 Mar;26(3):404-13. doi: 10.1089/thy.2015.0316. Epub 2015 Dec 14.
Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma
Lee DY11, Won JK2, Lee SH3, Park do J4, Jung KC2, Sung MW5, Wu HG6, Kim KH5, Park YJ4, Hah JH5.

Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.

Cancer Biomark. 2016;16(3):425-33. doi: 10.3233/CBM-160581.
Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer
Park S11, Park S1, Lee SH1,2, Suh B3, Ock CY1, Keam B1, Kim TM1, Kim DW1, Kim YW1, Heo DS1.

Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17.
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)
Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.

BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
Cha S11, Lee J2, Shin JY3, Kim JY4, Sim SH5, Keam B6,7, Kim TM8,9, Kim DW10,11, Heo DS12,13, Lee SH14,15,16,17, Kim JI18,19,20,21.

Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.

Oncotarget. 2015 Dec 22;6(41):43653-66. doi: 10.18632/oncotarget.6189.
Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas
Park CK11, Park I2, Lee S3, Sun CH3, Koh Y4, Park SH5, Kim JE1, Yun H3, Lee SH6.

J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692.
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors
Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.

J Thorac Oncol. 2015 Dec;10(12):1667-9. doi: 10.1097/JTO.0000000000000701.
The MISSION Impossible No, the Journey Should Continue with Better Targeting!
Lee SH11, Park K.

Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.

Oncotarget. 2015 Aug 21;6(24):20266-77.
Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas
Kim JE11, Cho HR2, Xu WJ3, Kim JY1, Kim SK4, Kim SK1,5, Park SH6, Kim H2, Lee SH7, Choi SH2, Park S3, Park CK1.

J Neurooncol. 2015 Aug;124(1):101-10. doi: 10.1007/s11060-015-1808-z. Epub 2015 May 31.
Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas
Kim BS11, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS.

PLoS One. 2015 Jul 22;10(7):e0133371. doi: 10.1371/journal.pone.0133371. eCollection 2015.
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
Kim M11, Ku JH2, Kwak C2, Kim HH2, Lee E2, Keam B3, Kim TM3, Heo DS3, Lee SH4, Moon KC5.

Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5.
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer
Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.

J Cell Biochem. 2005 Mar 1;94(4):695-707.
Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60
Han SS11, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.

Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8.
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission
Lee SH11, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.

Cell Signal. 2005 Jan;17(1):111-9.
Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells
Park S11, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.

Bone Marrow Transplant. 2003 Nov;32(9):889-95.
Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia
Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.